Fundz

Photopharmics Inc reported raising $2.65 Million in an initial SEC Form D filing, from an offering of $2.75 Million

PRIVATEMar 07, 2017$2.7M of $2.8M raised

Amount Raised

$2.65 Million

$2.65 Million sold, per SEC Form D (first sale Mar 7, 2017)

Round Type

Venture

American ForkInformation Technology

Quick answer

Photopharmics raised $2.65 Million in a funding round, dated March 7, 2017. Photopharmics is based in American Fork, Utah, United States.

How much did Photopharmics raise?
Photopharmics raised $2.65 Million in a funding round on March 7, 2017.
What does Photopharmics do?
PhotoPharmics is a pioneering biotechnology company specializing in the treatment of neurodegenerative disorders through the eyes.
Where is Photopharmics based and how big is it?
Photopharmics is based in American Fork, Utah, United States.
Who are the decision-makers at Photopharmics?
Fundz holds 1 contact at Photopharmics, including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Photopharmics, and when

A new round usually means Photopharmics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Photopharmics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Photopharmics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Photopharmics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Photopharmics

Location

3451 NORTH TRIUMPH BLVD

American Fork, Utah, United States

About

PhotoPharmics is a pioneering biotechnology company specializing in the treatment of neurodegenerative disorders through the eyes. With over 30 years of research and experience, the company has developed advanced light-based therapies that regulate circadian rhythms—helping millions manage conditions like Seasonal Affective Disorder (SAD), sleep disorders, anxiety, and depression. Building on its legacy of innovation (including technology acquired by Philips-Respironics in 2007), PhotoPharmics now focuses on diseases such as Parkinson’s, where retinal deterioration and circadian disruption play key roles. Their groundbreaking research in specialized wavelengths of light has led to a pivotal clinical trial aimed at reducing Parkinson’s symptoms, with results anticipated for publication in Autumn 2018.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Photopharmics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsKent S., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Photopharmics's next move

See what Strategic adds

Photopharmics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.